Neurocrine Biosciences (NBIX): Reiterating Overweight Ahead Of ASRM - Piper Jaffray

October 18, 2016 6:45 AM EDT
Get Alerts NBIX Hot Sheet
Price: $41.98 +4.51%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 21 | New: 54
Trade NBIX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Neurocrine Bio. (NASDAQ: NBIX) ahead of of Wednesday’s presentations at ASRM.

The analyst reviewed the efficacy and safety results on elagolix and other GnRH antagonists in development. Based on comparing the early Phase II data from potential competitors to the available Phase II & III elagolix data, the analyst sees only incremental, if any, benefits from these 2 nd-generation agents. Elagolix seems to have a clear advantage in terms of patients evaluated & efficacy/safety results to date, dosing flexibility (1-2x times daily and with or without add-back therapy), first-to-market status, and experienced commercial partner AbbVie.

No change to the price target of $96.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $42.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment